Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization: an In-vitro Analysis of Oxytocin Receptor Expression and Signaling

Not Applicable

Terminated

• Conditions: Postpartum Hemorrhage

• Registration Number: NCT02762669
• Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-5-3
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Terminated
• Sex: Female
• Target Recruitment: 4

Inclusion Criteria

Inclusion Criteria:<br><br> - Patients who give written consent to participate in this study<br><br> - Patients with gestational age 37-41 weeks<br><br> - Non-laboring patients, not exposed to exogenous oxytocin<br><br> - Patients requiring primary Cesarean delivery or first repeat Cesarean delivery<br><br>Exclusion Criteria:<br><br> - Patients who refuse to give written informed consent<br><br> - Patients who require general anesthesia<br><br> - Patients who had previous uterine surgery or more than one previous Cesarean<br> delivery<br><br> - Patients with any condition predisposing to uterine atony and postpartum hemorrhage,<br> such as abnormal placentation, multiple gestation, preeclampsia, macrosomia,<br> polyhydramnios, uterine fibroids, bleeding diathesis, chorioamnionitis, or a<br> previous history of postpartum bleeding<br><br> - Emergency Cesarean section in labor<br><br> - Patients on medications that could affect myometrial contractility, such as<br> nifedipine, labetolol or magnesium sulphate.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxytocin receptor (OTR) protein expression and localization

Secondary Outcome Measures

Name	Time	Method
Oxytocin receptor (OTR) phosphorylation patterns;Protein expression levels of PLC, MEK5 and ERK5